CALIDI BIOTHERAPEUTICS INC
CLDINYSE AMERICAN🏆 #4065 by market capUS Equity
$740.67▼ $11.48 (−1.55%)
Simulated price1h—
24h▼ 1.6%
7d—
14d—
30d—
1y—
🏦Market Cap
$2M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
50
Weak
No chart data available for CLDI.
Trading Snapshot
- Day Range
- $735.72 – $747.23
- 52-Week Range
- $1.48 – $98.72
- Volume
- $2.00B
- Avg Volume
- $1.80B
- Shares Outstanding
- 19.3M
- Next Earnings
- Oct 1, 2026
Fundamentals Snapshot
- Annual Revenue
- $129,375
- Last Q Revenue
- $30,970
- P/E Ratio
- —
- P/S Ratio
- —
- EPS (TTM)
- $-4.00
- Dividend Yield
- —
Why Investors Own CLDI
- ✓High-growth profile — revenue up +5.7% YoY with expanding US Equity exposure.
- ✓Healthy economics — 79% gross margin and 25% free-cash-flow margin.
- ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
Financial Trends
Revenue (TTM)
$129,375▲ +9.3% YoY
Gross Margin (TTM)
78.6%▲ +3.3% YoY
Operating Income (TTM)
$38,424▲ +9.3% YoY
Free Cash Flow (TTM)
$31,956▲ +9.3% YoY
About CALIDI BIOTHERAPEUTICS INC
A company profile for CALIDI BIOTHERAPEUTICS INC isn’t available yet — check back soon.
🦦
Otter Score Breakdown
ⓘ💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
Overall Score
Weak
50/100
Analyst Price Target
ⓘAverage Target
$777.86
▲ +5.0% Upside
High Target$934.53
Low Target$665.74
Based on 34 analysts
Latest News & Updates
🚀
Bloomberg·2h ago
CALIDI BIOTHERAPEUTICS INC tops quarterly estimates as demand accelerates
Revenue grew double digits with management guiding above consensus; margins continued to expand.
🛰️
MarketWatch·5h ago
Analysts lift CLDI price targets on improving margins
Several firms raised targets, citing stronger free cash flow and a healthier backlog.
🌌
CNBC·1d ago
CALIDI BIOTHERAPEUTICS INC announces new agreement to expand its footprint
The move broadens the company’s reach and could add incremental revenue over the next year.